Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of NASDAQ CARA opened at $0.30 on Friday. The stock has a market capitalization of $16.68 million, a PE ratio of -0.17 and a beta of 0.68. Cara Therapeutics has a one year low of $0.24 and a one year high of $1.31. The business’s fifty day moving average price is $0.29 and its 200-day moving average price is $0.37.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Disciplined Growth Investors Inc. MN lifted its position in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares in the last quarter. FMR LLC raised its stake in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Cara Therapeutics during the 3rd quarter worth about $29,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.